Levonorgestrel Intrauterine System Effects on Hemoglobin and Serum Ferritin Among Anemic Women in Kenya - Trial NCT05233956
Access comprehensive clinical trial information for NCT05233956 through Pure Global AI's free database. This phase not specified trial is sponsored by FHI 360 and is currently Not yet recruiting. The study focuses on Anemia. Target enrollment is 600 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
FHI 360
Timeline & Enrollment
N/A
Sep 01, 2023
Feb 01, 2026
Primary Outcome
Change in hemoglobin
Summary
Women with mild/moderate anemia who are seeking contraception will be randomized to a
 levonorgestrel (LNG) intrauterine system (IUS) or an LNG/ethinyl estradiol (EE)/ferrous
 fumarate combined oral contraceptive (COC) regimen and followed prospectively for 18 months.
 Approximately 600 participants will be enrolled. The primary hypothesis is that the mean
 change in hemoglobin concentration will be significantly higher in the group assigned to the
 LNG IUS compared to the group assigned to COCs
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05233956
Non-Device Trial